The Recall Desk
SevereFDA (Drugs)·D-0653-2026·Announced 2026-07-08

IMULDOSA injection recalled due to lack of sterility assurance

Accord BioPharma is recalling IMULDOSA (ustekinumab-srlf) Injection due to lack of assurance of sterility. The affected lot was distributed nationwide.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The FDA classified this as a Class II recall. A sterility defect in an injectable drug for systemic use poses risk of serious infection and potential hospitalization; lack of sterility assurance in a prescription injection product meets the Severe criteria.

Plain-English summary

Accord BioPharma Inc. is recalling IMULDOSA (ustekinumab-srlf) Injection, 130 mg/26 mL, a prescription medication administered by subcutaneous injection. The recall affects lot #004L24A with an expiration date of 02/19/2027, which comprises 326 vials distributed nationwide.

The recall is due to lack of assurance of sterility. Patients who have received this product should contact their healthcare provider. Healthcare providers should not dispense units from the recalled lot and should return any affected vials to Accord BioPharma Inc.

The recalled product

Product
IMULDOSA (USTEKINUMAB-SRLF)
Brand
IMULDOSA
Manufacturer
ACCORD BIOPHARMA INC
Hazard
  • sterility-defect
  • infection-risk

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot # 004L24A
  • Exp Date: 02/19/2027.

UPCs (2)

  • 0369448017637
  • 0369448018634

Distribution

Distributed nationwide across the United States.